Data | Number | BTNL2 | Univariate model raw p value *,** | ||
---|---|---|---|---|---|
A/A | G/A | G/G | |||
Epidemiological data | 0.59 | ||||
Ethnicity | 292 | ||||
European | 226 | 103 (75.7%) | 104 (80%) | 19 (73.1%) | |
Caribbean or Sub-Saharan African | 66 | 33 (24.3%) | 26 (20%) | 7 (26.9%) | |
Clinical data at diagnosis | |||||
Disease onset | 389 | 0.91 | |||
Asymptomatic | 130 | 60 (34.29%) | 59 (33.15%) | 11 (30.56%) | |
Symptomatic | 259 | 115 (65.71%) | 119 (66.85%) | 25 (69.44%) | |
Löfgren syndrome | 368 | 0.042 [0.42] | |||
Yes | 58 | 25 (14.71%) | 32 (19.39%) | 1 (3.03%) | |
No | 310 | 145 (85.29%) | 133 (80.61%) | 32 (96.97%) | |
Number of organs involved | 397 | 0.074 | |||
1 | 152 | 70 (38.46%) | 73 (41.01%) | 9 (24.32%) | |
2 | 115 | 55 (30.22%) | 49 (27.53%) | 11 (29.73%) | |
3 | 66 | 29 (15.93%) | 33 (18.54%) | 4 (10.81%) | |
≥ 4 | 64 | 28 (15.39%) | 23 (12.92%) | 13 (35.14%) | |
Organs involved | 397 | 0.082 | |||
Lungs only | 143 | 68 (37.36%) | 67 (37.64%) | 8 (21.62%) | |
Lungs and Eyes | 52 | 23 (12.64%) | 20 (11.24%) | 9 (24.33%) | |
Lungs and Skin | 20 | 11 (6.04%) | 8 (4.49%) | 1 (2.7%) | |
Other sites | 182 | 80 (43.96%) | 83 (46.63%) | 19 (51.35%) | |
X-ray staging | 432 | 0.26 | |||
0 | 57 | 25 (12.5%) | 26 (13.47%) | 6 (15.38%) | |
1 | 158 | 77 (38.5%) | 65 (33.68%) | 16 (41.03%) | |
2 | 149 | 67 (33.5%) | 68 (35.23%) | 14 (35.9%) | |
3 | 47 | 24 (12%) | 22 (11.4%) | 1 (2.56%) | |
4 | 21 | 7 (3.5%) | 12 (6.22%) | 2 (5.13%) | |
PFT at first visit | |||||
TLC (%) | 0.098 | ||||
< 80% | 47 | 23 (24.47%) | 22 (23.91%) | 2 (9.52%) | |
≥ 80% | 160 | 71 (75.53%) | 70 (76.09%) | 19 (90.48%) | |
Pattern of disease course | |||||
SCAC | 398 | 0.83 | |||
1- symptomatic - no treatment | 46 | 21 (11.6%) | 22 (12.1%) | 3 (8.3%) | |
2- symptomatic - treatment ≤ 12 mo. | 47 | 19 (10.5%) | 22 (12.1%) | 6 (16.7%) | |
3- symptomatic - treatment > 12 mo. | 166 | 75 (41.4%) | 74 (40.9%) | 17 (47.2%) | |
4- asymptomatic - no treatment | 48 | 19 (10.5%) | 26 (14.4%) | 3 (8.3%) | |
5- asymptomatic - treatment ≤ 12 mo. | 14 | 6 (3.3%) | 7 (3.9%) | 1 (2.8%) | |
6- asymptomatic - treatment > 12 mo. | 77 | 41 (22.7%) | 30 (16.6%) | 6 (16.7%) | |
Classification of outcome | 137 | 0.015 [0.14]*** | |||
1- recovery within 3 years | 72 | 29 (52.73%) | 36 (52.17%) | 7 (53.85%) | |
2- recovery between 3 and 5 years | 32 | 9 (16.36%) | 17 (24.64%) | 6 (46.15%) | |
3- no recovery at 5 years | 29 | 15 (27.27%) | 14 (20.29%) | 0 (0%) | |
4- death | 4 | 2 (3.64%) | 2 (2.9%) | 0 (0%) |